OS Therapies Incorporated (OSTX) Fair Value 2026

OSTX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.0 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, OS Therapies Incorporated (OSTX) trades at $1.64. QOC: 4.0/10. Value Trap Risk: 21/100 (SAFE). 1/13 models active.

Key Facts

Ticker
OSTX
Price
$1.64
Quality Score
4.0/10
Value Trap Risk
21/100
Models Active
1/13
Last Updated
Strength: Regime Cross-Sectional suggests +17.4% upside with 47% confidence
Risk: Below-average Quality Score of 4.0/10 signals weak fundamentals

What Fair Value Does Each Model Give OSTX?

1 Intrinsic Value Models vs. Current Price ($1.64)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $1.93 +17.4%

All Models Active

All 1 models are displayed above.

What Is OS Therapies Incorporated (OSTX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, OS Therapies Incorporated's intrinsic value is estimated at a median fair value of $1.93. At a current market price of $1.64, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +17.4%.

What Do the Models Say About OSTX?

1 of 13 models are currently active for OSTX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does OSTX Rank in Biotechnology?

Among 625 Biotechnology stocks, OSTX ranks #532 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

OS Therapies Incorporated's positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is OSTX a Value Trap?

CirclFi's Value Trap algorithm assigns OSTX a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for OS Therapies Incorporated. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, OS Therapies Incorporated earns a quality score of 4.0/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every OSTX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across OSTX's 1 active models, average confidence is 47%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy OS Therapies Incorporated Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

GNPXGenprex, Inc.QOC 4.1VBIOValion Bio, Inc.QOC 4.0BIXTBioxytran, Inc.QOC 4.1DRMADermata Therapeutics, Inc.QOC 4.0PDSBPDS Biotechnology CorporationQOC 4.1NERVMinerva Neurosciences, Inc.QOC 4.0CSBRChampions Oncology, Inc.QOC 6.8IPHAInnate Pharma S.A.QOC 5.5TTRXTurn Therapeutics Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: GNPX · VBIO · BIXT · DRMA · PDSB · NERV · CSBR · IPHA · TTRX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to OSTX?

7 companies across all industries closest to OSTX’s Quality of Company score of 4.0/10.

ELBMElectra Battery Materials CorporationQOC 4.0CLOQCyberloq Technologies, Inc.QOC 4.0BLISNAPC Defense IncQOC 4.0MVISMicroVision, Inc.QOC 4.0HWNIHigh Wire Networks Inc.QOC 4.0SOCSable Offshore Corp.QOC 4.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ELBM · CLOQ · BLIS · MVIS · HWNI · SOC · NVDA

Where Does OSTX Sit in CirclFi's Biotechnology Rankings?

OSTX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About OS Therapies Incorporated’s Valuation?

What is OS Therapies Incorporated's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for OS Therapies Incorporated (OSTX). The Quality of Company score is 4.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is OSTX overvalued or undervalued right now?

At $1.64, 1 of 1 active models suggest OSTX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits OS Therapies Incorporated's business model in Biotechnology.

What does a Quality of Company score of 4.0 mean for OSTX?

OS Therapies Incorporated's QOC of 4.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on OSTX?

CirclFi analyzes OSTX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is OSTX a value trap in 2026?

OS Therapies Incorporated's Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns OS Therapies Incorporated (OSTX) a Quality of Company score of 4.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/OSTX/ · Methodology
Primary sources for this OSTX valuation
  • Financial statements: OS Therapies Incorporated 10-K and 10-Q filings on SEC EDGAR (CIK 0001795091) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for OSTX as of ; valuations recomputed .